We focus on areas of significant unmet medical need and areas where we have the expertise to make a difference.
  • Focused on translating excellence in science into breakthrough medicines for patients

  • One of the leading developers of targeted treatments combined with corresponding diagnostics

  • The world’s largest biotech company

  • The world’s leading provider of cancer treatments

Roche Pharmaceuticals is focused on translating excellence in science into effective medicines for patients in oncology, neurosciences, rare diseases, immunology, infectious diseases, hematology, hemophilia, and respiratory diseases. We combine cutting-edge research at Roche, Genentech in the U.S., Chugai in Japan and over 150 partners worldwide with strength in clinical development, manufacturing and commercial operations. We look for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care. Thanks to our Pharmaceuticals Division’s broad-based portfolio, we are one of the world’s leading providers of clinically differentiated medicines.

Roche Pharmaceuticals is living proof that scientific invention leads to products that truly improve patients’ lives. Our inspiring tradition of excellence in science dates back more than a century. Today, as then, our strategy is rooted in fostering excellence in science and empowering scientists to create breakthroughs in life science that will make a difference tomorrow.

In Canada, Roche Pharmaceuticals employs more than 850 people in its commercial organization, as well as Global Product Development, Information Technology, and Procurement functions. In 2011, Roche invested more than $190 million into expanding its site in Mississauga, Ontario. In addition to serving as the home for its Pharmaceutical Division, the site also houses one of five Roche global Product Development sites, which contributes to all phases of clinical trial development, including overseeing clinical studies in Canada, as well as some studies in the United States. The expansion project was supported by a $7.79 million investment from the Government of Ontario and brought close to 500 highly skilled and specialized jobs to the province.

Through continued investment and expansion of its operations in Mississauga, Roche has made a sizeable impact to the Canadian economy, including $1.1 billion in Gross Domestic Product generated over the past five years.  

In 2017, Roche invested over $52 million inmaking it a key country in which we pilot new initiatives. Today, there are approximately 160 Roche-sponsored clinical trials underway in Canada, offering people living with a variety of conditions an opportunity to help move medical science forward by working with us to test new treatments.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactWorldwidelinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsDiagnostics solutionCareersMediaPrivacy policyLegal statementSocial Media PolicyAccessibility

You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.